Kornimate/medical-research-clean huggingface dataset:
the role of 68ga-fapi-04 pet/ct as a problem solving imaging modality in various malignancies

Conditions: Different Types of Cancer

Summary: the aim of the suggested study is to assess the added value of 68ga-fapi-04 pet/ct over 18f-fdg pet/ct in evaluating the extent of disease in patients with various malignancies, in whom a diagnostic challenge is met, such as inconclusive findings on 18f-fdg pet/ct or other imaging studies, better delineation of tumor extent prior to therapy, and with emphasis on malignancies known to show variable avidity to fdg and at times, no uptake at all. also patients unable to optimally comply with the required preparation for fdg imaging, such as diabetic patients who struggle in achieving glycemic control.


Eligibility criteria:
inclusion criteria: the study population will include up to 50 patients with disease in whom a diagnostic challenge is met, including but not limited to: 1. inconclusive findings on 18f-fdg pet/ct or other imaging modalities. 2. better delineation of tumor extent prior to therapy 3. malignancies known to show variable avidity to fdg and at times, no uptake at all (e.g. exocrine pancreatic cancer, gastric carcinoma, mucin-producing or signet-ring carcinoma). 4. patients unable to optimally comply with the required preparation for fdg imaging. * the study population will include only patients treated in tel-aviv sourasky medical center, tel-aviv, israel, and referred by their attending physicians, of whom are part of the hospital staff. exclusion criteria: * age \< 18 years. * pregnant females. * patients who are reluctant to undergo both fdg and fapi pet scans.
the effects of chia on overweight/obese women

Conditions: Obesity; Eating Behavior; Mood; Glucose; Dietary Modification

Summary: the purpose of the study is to examine the effect of chia seed consumption on body composition, blood pressure, blood glucose, satiety, mood, joint pain, and dietary displacement in overweight and obese females (18-45years). it is hypothesized that consuming chia seeds will bring about a positive change in body composition (lower % body fat), satiety, mood, joint pain, and blood pressure, lower blood glucose levels, increased fiber and improved nutrient intake, in overweight/ obese females.

specific objectives: 1. determine if chia seed diet addition of 10% of kcals (chia) positively changes body composition in young, healthy, overweight/obese people (tanita scale). a) determine if chia will decrease blood pressure (monitor). 2. determine if chia will decrease blood glucose (draw) 3. determine if chia increases satiety and improves diet (recordings). 4. determine if chia will decrease joint pain (questionnaire). 5. determine if chia will increase positive mood changes (questionnaires) and increase blood serotonin levels (draw).

Eligibility criteria:
inclusion criteria: * are a female. * are between the ages of 18 and 45. * are not averse to consuming chia seeds on a regular basis (at least six weeks). * have not taken any medication for any chronic disease (heart, diabetes, cancer) for twelve weeks. * have not taken any steroid or hormone medication in the last eight weeks, excluding birth control pills... * do not consume excess amounts of nuts and seeds. - do not consume alcohol on a regular basis. * are not currently on a diet plan. * are not pregnant or plan to become pregnant. exclusion criteria: * are a child, teenager, woman, or male younger than 18 or older than 45. * eat large quantities of chia seeds on a regular basis. * are taking any steroid or hormone medication (other than birth control pills). - are taking laxatives or fiber containing supplements on a regular basis. * are pregnant or become pregnant. * are currently on a diet plan. * have a known allergy to seeds. * consume excess amounts of seeds or nuts. * consume alcohol on a regular basis. * have a pacemaker or metal pins or plates in the body.
relevance of plasma pcsk9 concentration as a biomarker in acute coronary syndrome.

Conditions: Acute Coronary Syndrome

Summary: pcsk9 (proprotein convertase subtilisin kexin type 9) plays a key role in ldl-cholesterol (ldlc) metabolism by inhibiting ldl receptor (ldlr) at post-transcriptional level. pcsk9 loss of function mutations are associated to decreased ldlc levels and a cardiovascular protection. in this context, the development of pharmacological inhibitors of pcsk9, in association with statins treatment, represents a major therapeutic issue for ldlc modulation. it was previously shown that pcsk9 plasmatic concentration correlated with plasmatic ldlc, tg and glucose concentrations. however, no data are available on predictive value of pcsk9 plasmatic level concerning coronary disease severity. the main objective of this study is to determine whether plasmatic pcsk9 concentration is linked to coronary damage severity in patients with acute coronary syndrome.


Eligibility criteria:
inclusion criteria: * more than 18 years old * acute coronary syndrome (st+ or st-) * 2 groups of patients: with statin, and without statin treatment exclusion criteria: * patient who had cancer during the last 5 years or with cancer in progress * patient with severe infection in progress * hepatic failure (tp\<50%) * severe kidney failure * patient unable to give his consent to the study

Keywords: acute coronary syndrome pcsk9 cardiovascular safety
interactions of hiv protease inhibitors and methadone in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe to combine methadone with two hiv protease inhibitors (pis), ritonavir (rtv) and saquinavir (sqv), in hiv-infected patients not currently taking pis. this study will measure the interactions between methadone and the pis. methadone is used treat addicts and to treat severe pain. in order to find the safest way to use methadone with pis, it is important to evaluate how they interact.

methadone is extensively used in the maintenance treatment of addicts and in the management of severe pain. in order to use methadone with hiv protease inhibitors correctly, it is important to evaluate and quantify interactions between the protease inhibitors and methadone. patients receive their usual daily dose of methadone followed with ritonavir and saquinavir, respectively, twice a day. patients are evaluated on day 4 for safety and tolerance, and their ritonavir dose is increased. on day 8 patients are evaluated for a steady-state level of methadone. after 2 weeks of the protease inhibitor therapy, they return for methadone pharmacokinetic sampling at day 15 over 24 hours. both protease inhibitors and methadone are administered on day 15 on an inpatient basis. on day 30, patients are assessed for safety and tolerance.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive and have an hiv rna count below 100,000 copies/ml within 30 days prior to study entry. * are taking methadone. * are at least 18 years old. * are within 40% of your ideal body weight and weigh at least 99 lbs. exclusion criteria you will not be eligible for this study if you: * are allergic to or are unable to take rtv or sqv. * have a history of treatment failure with indinavir, rtv, or sqv. * have a history of certain illnesses that might prevent you from completing the study. * have severe diarrhea or other stomach problems. * have taken any pi within 4 weeks prior to study entry. * would be unable to complete the study due to alcohol or drug abuse. * are co-enrolled in other protocols that have you taking medications that are prohibited in this study. * are taking pis other than rtv or sqv. * are receiving certain therapies or are taking certain medications, including experimental drugs. * have an active opportunistic (aids-related) infection or disease that requires medication within 14 days prior to study entry. * are pregnant or breast-feeding.

Keywords: methadone hiv-1 dose-response relationship, drug drug interactions drug therapy, combination saquinavir adolescent behavior hiv protease inhibitors ritonavir narcotics substance-related disorders
probiotics as a novel approach to modulate gut hormone secretion and risk factors of type 2 diabetes and complications

Conditions: Obesity; Type 2 Diabetes

Summary: the investigators aim to test the hypothesis that lactobacillus reuteri-enriched microbiota improves insulin sensitivity and glucose tolerance in obese healthy and obese type 2 diabetes patients by improving gut hormone secretion and compare these findings to healthy lean subjects.

prediabetes and diabetes are accompanied by insufficient gut hormone release, insulin resistance, insufficient insulin secretory capacity and low grade systemic inflammation. results of recent animal experiments suggest that ingestion of probiotics not only influences gut microbiota composition and intestinal permeability but also secretion of glp-2 as well as insulin resistance, components of metabolic syndrome and diabetes development. glp-2 secretion has been suggested to be a key mediator of probiotic effects mediating decreased intestine permeability through binding to intestinal glp2 receptor in animal studies. insulinotropic glp-1, which is reduced in patients with type 2 diabetes, has also been described to be influenced by gut microbiota composition. we aim to test the hypothesis that lactobacillus reuteri-enriched microbiota improves insulin sensitivity and glucose tolerance in obese healthy and obese type 2 diabetes patients by improving gut hormone secretion. in a prospective, double-blinded, placebo controlled randomized 10 weeks trial we aim to investigate metabolic and immunological changes related to modified gut microbiota by analysing (1) gut hormone secretion, (2) insulin sensitivity and glucose tolerance, and (3) systemic lps concentrations and immune status.

Eligibility criteria:
inclusion criteria: * obese subjects: age 40 - 65 years, obesity (bmi 30-45 kg/m2), non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks. * healthy control subjects: non-obese (bmi 19-25 kg/m2), non-diabetic subjects, matched for age and sex, non-smoking, absence of gastrointestinal disease, willingness to abstain from intake of fermented milk products over a study period of 8 weeks. exclusion criteria: * pregnancy, cancer, chronic diseases, antibiotic therapy, competitive athletes.

Keywords: probiotics prevention dietary intervention insulin resistance obesity type 2 diabetes
alimta(pemetrexed)/cisplatin and alimta(pemetrexed)/carboplatin in extensive stage small cell lung cancer.

Conditions: Lung Neoplasms

Summary: the purpose of this study is to evaluate the effects (good and bad) of alimta plus carboplatin or alimta plus cisplatin on you and your small cell lung cancer.


Eligibility criteria:
inclusion criteria: * have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy. * have received no prior chemotherapy for your disease. * have at least one measurable lesion. * have an adequate performance status. * sign an informed consent form. exclusion criteria: * have previously received chemotherapy for your lung cancer. * have been treated with a investigational drug within the last 30 days. have previously completed or withdrawn from this study or any other study investigating alimta. * have received radiation therapy within the last 1-2 weeks. * have brain metastasis that is uncontrolled. * have active infection or other serious condition.
predictors of intestinal anastomosis leakage, application of new predictors and new scores

Conditions: Anastomotic Leak

Summary: aim of the work this study aims at; early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.


Eligibility criteria:
inclusion criteria: * any patient with intestinal or colonic anastomosis either elective or emergent. exclusion criteria: * patients with inflammatory bowel disease will be excluded because this could influence plasma levels of inflammatory biomarkers. * patients using corticosteroids * patients unfit for anaesthesia, those having collagen diseases or hematological disorders.
autologous car-t/tcr-t cell immunotherapy for malignancies

Conditions: B-cell Acute Lymphoblastic Leukemia; Lymphoma; Myeloid Leukemia; Multiple Myeloma; Hepatoma; Gastric Cancer; Pancreatic Cancer; Mesothelioma; Colorectal Cancer; Esophagus Cancer; Lung Cancer; Glioma; Melanoma; Synovial Sarcoma; Ovarian Cancer; Renal Carcinoma

Summary: this is a single arm, open-label, uni-center, phase i-ii study to evaluate the safety and effectiveness of car-t/tcr-t cell immunotherapy in treating with different malignancies patients.

the study is a multi-target gene-modified immunotherapy. car-t/tcr-t cells include ten different tumor-specific antibody.they are as following:anti-cd19 antibody for b cell leukemia and lymphoma;anti-cd22 antibody for b cell leukemia and lymphoma;anti-cd33 antibody for myeloid leukemia;anti-bcma antibody for multiple myeloma;anti-cd38 antibody for multiple myeloma;anti-ny-eso-1 antibody for multiple myeloma,esophagus cancer,lung cancer,melanoma and synovial sarcoma;anti-dr5 antibody for hepatoma;anti-c-met antibody for hepatoma,colorectal cancer,ovarian cancer and renal carcinoma;anti-egfr v iii antibody for hepatoma,lung cancer and glioma;anti-mesothelin antibody for gastric cancer,pancreatic cancer and mesothelioma.

Eligibility criteria:
inclusion criteria: 1. if patients had receive immunotherapy, they should reach pr/nr, or recurrency. 2. patients must be willing to sign an informed consent. 3. age: 4 to 70 years 4. estimated survival of ≥ 12 weeks, but ≤ 2 years 5. blood tumor or solid tumor was diagnosed by histopathology.positive expression of cd19, cd22, cd33, cd38, bcma, ny-eso-1, c-met, mesothelin, cegfrviii and dr5 was confirmed by biopsy ihc test or flow cytometry test. if ny-eso-1 is positive expression ,positive hla-a\*0201 is required at the same time . 6. subjects with solid tumor must have measureable disease 7. routine blood test：hemoglobin\>=90 g/l; platelet\>=50×10\^9/l. 8. renal function:bun: 9-20mg / dl; serum creatinine\ =50 ml/min 9. negative serum antibody for ebv, cmv, hiv , syphilis, hbva nd hcv(patients with liver cancer were excluded) 10. cardiac function: stable hemodynamic and left ventricular ejection fraction (lvef)\>=55%. 11. ecog score ≤2 12. adequate venous access for apheresis, and no other contraindications for leukapheresis 13. women of child-bearing age must have evidence of negative pregnancy test. 14. subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol. exclusion criteria: 1. ecog \>= 3 2. patients with history of t cell tumors 3. patients with severe insufficient cardiac, pulmonary and hepatorenal functions 4. acute or chronic gvhd after allogeneic hematopoiesis 5. steroid hormoneswere used before and after blood collection and infusion 6. hiv infection or active hepatitis b or hepatitis c infection 7. uncontrolled active infection 8. enrolled to other clinical study in the last 4 weeks. 9. subjects with systemic auto-immune disease or immunodeficiency. 10. subjects with cns diseases. 11. other patients that researchers considered unsuitable for inclusion
cartilage injury and remodeling after acl rupture and reconstruction: functional imaging and biomarkers

Conditions: Anterior Cruciate Ligament Injuries

Summary: the proposed study will establish novel relationships between intra-articular msc recruitment, synovial inflammation, biomarkers of cartilage degeneration and joint inflammation, clinical patient factors, and downstream alterations in cartilage composition and morphology to provide novel insights into the pathoetiology of ptoa after acl injury and reconstruction.

in efforts to study the pathoetiology of post-traumatic osteoarthritis (ptoa), we propose a collaborative, prospective cohort study of 38 patients undergoing primary anterior cruciate ligament (acl) reconstruction after acl rupture. we will assess the longitudinal progression of patient-reported outcomes, knee laxity, mri-based articular cartilage morphology and composition, and serum-borne biomarkers of cartilage degeneration up to 1 year of follow-up. furthermore, stem cell mobilization, chemokine and pro-inflammatory cytokine concentrations, and inflammatory cell recruitment into synovial tissue will be measured from intraoperatively-collected samples. we will perform mixed multivariate linear regression modeling to elucidate potentially novel relationships between patient demographics, anatomy, biological factors, and downstream alterations in articular cartilage morphology and composition. we request $200,000 in funding over a two-year duration.

Eligibility criteria:
inclusion criteria: * - males and females, aged 18 - 30 years * isolated, traumatic primary anterior cruciate ligament rupture requiring surgical reconstruction * surgical reconstruction performed using a single-bundle technique utilizing an autograft * no history of ipsilateral traumatic knee injury or fracture * no evidence of pcl injury or more than grade 1 injury to the mcl or lcl exclusion criteria: * - bmi \ 35 kg/m2 * injury occurred longer than 4 weeks before enrollment * intra-articular steroid injection within 3 months of injury * chondral defects greater than 3 cm2 or outerbridge grade ii or higher lesions
rifaximin use in severe alcoholic hepatitis

Conditions: Severe Alcoholic Hepatitis

Summary: this study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.


Eligibility criteria:
inclusion criteria: * heavy alcohol drinking within 3 months (over 40 g/day) * maddrey's discriminant function ≥ 32 * ast/alt ration ≥ 2 * bilirubin level ≥ 5mg/dl * any one of the following additional criteria : hepatic encephalopathy, enlarged, tender liver, or peripheral leucocytosis * age : 19-75 * jaundice within 3 months exclusion criteria: * other causes of chronic liver disease (hbv, hcv, or autoimmune hepatitis) * antibiotics or probiotics use within 8 weeks * drug induced hepatotoxicity * acute viral hepatitis (hav or hev) * hepatic abscess or cholagitis * hepatocellular carcinoma of modified uicc stage ii, iii or iv * malignant tumor other than hcc * pregnancy * severe chronic extrahepatic disease * type i hepatorenal syndrome * hepatic encephalopathy grade ii or iv * severe infection
clinical and molecular correlations in spinocerebellar ataxia type 10 (sca10)

Conditions: Hereditary Ataxia

Summary: objectives: i. clinically evaluate members from families with a dominantly inherited ataxia and collect blood, skin and muscle samples for detailed molecular studies. ii. perform detailed clinical evaluations on patients with recessively inherited ataxias.

protocol outline: participants undergo a comprehensive clinical and molecular evaluation. studies include: neurologic evaluation, including magnetic resonance imaging and nerve conduction studies; ophthalmologic exam; audiologic exam, including auditory brain stem evoked response; dna extraction from blood, skin and muscle; genotype phenotype correlation. a neuropathologic evaluation is conducted postmortem, when possible.

Eligibility criteria:
inclusion criteria: subjects who have the diagnosis of sca10 and their immediate relatives. exclusion criteria: children under 3 years of age, pregnant women, prisoners, mentally incapacitated subjects, and subjects who do not give consent.

Keywords: hereditary ataxia neurologic and psychiatric disorders rare disease
effect of obesity on extracellular matrix composition

Conditions: Adipose Tissue

Summary: the experiment is a simple cross-sectional study with three groups (n=10) in each group, young and old healthy men and obese young men. the study will investigate the composition of the adipose tissue extra cellular matrix. the main questions to answer, - is there differences in the adipose tissue extracellular matrix in obese compared to young men is there differences in the adipose tissue extracellular matrix in old compared to young men

three groups of young (n=10) and old (n=10) healthy men and obese young (n=10) men are recruited. after verbal and written information is provided signed consent is obtained. subjects arrive at the lab overnight fasted and not having done exercise the prior day and having consumed a normal isocaloric carbohydrate rich diet. after a voiding and a 15 min rest body composition is determined by dxa. after this blood pressure is measured in the supine position in triplicate separated by 1 min. following this a venous blood sample is obtained from a cubital vein, and kept on ice until further handling. subsequently an adipose tissue biopsy is obtained by the bergström technique applied with suction from an incision 3-5 cm lateral from the umbilicus. after compression and a 30 min rest, the subject perform an incremental exercise test to determine maximal fat oxidation. in brief pulmonary oxygen uptake and carbon dioxide excretion is measured using a cosmed quark b2 on-line system during 5 min rest sitting on a cycle ergometer, and then during exercise with 3 min increments starting at 60 watt and increasing by 35 watts. when the respiratory exchange ratio is above 1 the exercise is stopped. after a 5 min break an incremental test until voluntary exhaustion is performed to determine maximal oxygen uptake. this completes the experiment.

Eligibility criteria:
inclusion criteria: * healthy men aged \[18,35\] and bmi \[20,25\] * obese men aged \[18,35\] and bmi \[30,40\] * healthy older men aged \[60,75\] and bmi \[20,25\] exclusion criteria: * present or former cardiovascular disease and chronical inflammatory disease * consumption of medications and supplements that influence substrate use at rest and/or during exercise

Keywords: extracellular matrix compostion obesity age